European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Unleashing the curative potential of cancer immunotherapy

Descrizione del progetto

Virus ingegnerizzati contro il cancro

Il rapporto tra infezioni microbiche e regressione del tumore è nota fin dal 3000 a.C. Da allora, sono stati segnalati diversi virus oncolitici con benefici terapeutici. Sebbene l’efficacia sia migliorata grazie all’ingegneria genetica, siamo ancora lontani dall’applicazione clinica dei virus oncolitici. Il progetto UNLEASHAD, finanziato dall’UE, ha sviluppato un prodotto oncolitico basato sull’adenovirus, TILT-123, che colpisce e lisa in modo specifico le cellule tumorali. Inoltre, rilascia le citochine TNF-α e interleuchina-2 nel microambiente, creando un allerta e attirando le cellule immunitarie verso il tumore. Questa strategia assicura l’immunità antitumorale e può essere adatta ai tumori refrattari ad altri tipi di immunoterapia.

Obiettivo

TILT Biotherapeutics is developing a breakthrough oncolytic immunotherapy for treatment for cancer. Advanced solid tumors are currently incurable and limited treatment options are available – preclinical data on TILT technology suggests curative potential. There are over 9 million people dying from cancer each year and the incidence is growing rapidly. New immunotherapies for cancer are more widely available in America than in Europe partly because clinical research concentration in the U.S. Cancer patients also in Europe are in the increasing need of new treatment options.

The objective of this project is to generate a clinical proof-of-concept for the company’s lead product, TILT-123 alone and given with anti-PD(L)1 therapy in metastatic melanoma and other advanced solid tumors by completing Phase I clinical development. This project will last in total about 3,5 years and allow the company to confirm safety in human for TILT-123 as well as to generate mechanism of action data. Eventually, this could result in improved treatment responses in currently incurable anti-PD(L)1 refractory patients with melanoma and other solid tumor types.

TILT-123 is now entering clinical stage with all the key proof-of-concept and safety already demonstrated. Pilot and GMP-grade product production is completed and authorization for the first-in-man clinical trial in Denmark was obtained. EU support continues to be critical to launch this project onto clinical path. Actors from at least five different European countries are involved, underlining project’s EU-wide relevance. From the business perspective, this project would allow the company to mature into a stage from where its further development could be privately funded and supported by a pharmaceutical company. TILT Biotherapeutics will invest into further development of its pipeline projects, create more employment and business locally in Finland and Europe, and to bring an innovative treatment option with curative potential to the reach of European cancer patients.

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEInst-2018-2020-2

Meccanismo di finanziamento

SME-2 - SME instrument phase 2

Coordinatore

TILT BIOTHERAPEUTICS OY
Contribution nette de l'UE
€ 1 770 125,00
Indirizzo
C/O BIOMEDICUM 2B TUKHOLMANKATU 8B
00290 Helsinki
Finlandia

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Regione
Manner-Suomi Helsinki-Uusimaa Helsinki-Uusimaa
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 2 528 750,00